Chronic limb threatening ischemia

Chronic limb threatening ischemia (CLTI), also known as critical limb ischemia (CLI), is an advanced stage of peripheral artery disease (PAD). It is defined as ischemic rest pain, arterial insufficiency ulcers, and gangrene. The latter two conditions are jointly referred to as tissue loss, reflecting the development of surface damage to the limb tissue due to the most severe stage of ischemia. Compared to the other manifestation of PAD, intermittent claudication, CLI has a negative prognosis within a year after the initial diagnosis, with 1-year amputation rates of approximately 12% and mortality of 50% at 5 years and 70% at 10 years.^[1]

CLI was conceived to identify patients at high-risk for

Critical limb ischemia includes rest pain and tissue loss.^[citation needed]

Rest pain

Rest pain is a continuous burning

Other factors which may point to a diagnosis of critical limb ischemia are a Buerger's angle of less than 20 degrees during Buerger's test, a capillary refill of more than 15 seconds or diminished or absent pulses.^{[citation needed]}

Critical limb ischemia is different from

Other diagnostic approaches for CLI under development or that have recently been introduced include different angiographic and imaging techniques, as well as the use of biosensors.^[4]

2D perfusion imaging is a software analysis package that can be incorporated into a standard

Fluorescence angiography enables the visualization of regional blood flow using a charge-coupled camera. A 2016 study determined that it “is a valuable tool in visualizing real-time procedural outcomes and providing additionally useful information on regional tissue perfusion.” ^[6]

Biosensors measuring oxygen levels subcutaneously in the feet of CLI patients have been developed. Initial studies show these sensors may have value in predicting wound healing in CLI patients.^[7] One such sensing system, known as Lumee Oxygen, manufactured by Profusa Inc, attained European Regulatory approval in 2020.^[8]

Treatment

Treatment mirrors that of other symptoms of peripheral artery disease, and includes modifying risk factors, revascularization via vascular bypass or angioplasty, and in the case of tissue loss, wound debridement.^{[citation needed]} A randomised trial involving people with chronic limb threatening ischaemia who needed revascularisation below the knee found that offering endovascular therapy first led to better outcomes (fewer deaths and amputations) than offering vein bypass first (among people who were eligible for both surgeries).^[9][10]

Research

As of 2015 pCMV-vegf165, a gene-therapy was being studied in critical limb ischemia.^[11] In 2014, a trial was started to better understand the best revascularization technique for CLI. As of 2017, it had enrolled nearly half of the 2100 people needed to complete the trial.^[12] A similar study, BASIL 2 (Bypass Versus Angio plasty in Severe Ischaemia of the Leg), is being conducted in the United Kingdom.^[13]

References